Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of T2345 (Monopost) in Glaucoma
NCT01156012Phase 3Completed
- Sponsor
- Laboratoires Théa
- Start
- Sep 2009
- Primary completion
- Dec 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of latanoprost in Glaucoma and ocular hypertension (2 arms), sponsored by Laboratoires Théa. Primary endpoint: Change From Baseline in Intraocular Pressure at Day 84. Started Sep 2009; status: completed.
02
Drugs
latanoprost
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT01156012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01156012.